Apimeds Pharmaceuticals US, Inc. Total Assets
Apimeds Pharmaceuticals US, Inc. total assets. Based on the latest financial reports, Apimeds Pharmaceuticals US, Inc. (APUS) holds total assets worth $141.22 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see APUS cash flow conversion for how efficiently the company converts equity into cash flow.
Total Assets of Apimeds Pharmaceuticals US, Inc. (2021–2025)
Total assets of Apimeds Pharmaceuticals US, Inc. from 2021 to 2025. This chart illustrates how Apimeds Pharmaceuticals US, Inc.'s total assets have evolved over time, based on quarterly financial data. See latest Apimeds Pharmaceuticals US, Inc. stock price today for real-time trading data and today's change.
Apimeds Pharmaceuticals US, Inc. - Asset Composition Analysis
Apimeds Pharmaceuticals US, Inc. Total Assets Breakdown (December 2025)
Apimeds Pharmaceuticals US, Inc. total assets breakdown as of December 2025. Apimeds Pharmaceuticals US, Inc.'s total assets of $141.22 Million consist of 8.5% current assets and 91.5% non-current assets. Explore working capital to net assets of Apimeds Pharmaceuticals US, Inc. to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 1.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Apimeds Pharmaceuticals US, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Apimeds Pharmaceuticals US, Inc.'s current assets represent 8.5% of total assets in 2025, a decrease from 100.0% in 2021.
- Cash Position: Cash and equivalents constituted 1.0% of total assets in 2025, down from 99.6% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Apimeds Pharmaceuticals US, Inc. Competitors by Total Assets
Key competitors of Apimeds Pharmaceuticals US, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
|
Zhejiang Medicine Co Ltd
SHG:600216
|
China | CN¥14.18 Billion |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799
|
China | CN¥2.53 Billion |
|
Dezhan HealthCare Co Ltd
SHE:000813
|
China | CN¥4.77 Billion |
|
Chongqing Pharscin Pharmaceutical Co Ltd
SHE:002907
|
China | CN¥2.00 Billion |
Apimeds Pharmaceuticals US, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.90 | 0.15 | 0.02 |
| Quick Ratio | 0.90 | 0.15 | 0.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.43 Million | $-1.51 Million | $-313.61K |
Apimeds Pharmaceuticals US, Inc. - Advanced Valuation Insights
This section examines the relationship between Apimeds Pharmaceuticals US, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.05 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 1257338.4% |
| Total Assets | $164.18 Million |
| Market Capitalization | $4.84 Million USD |
Valuation Analysis
Below Book Valuation: The market values Apimeds Pharmaceuticals US, Inc.'s assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Apimeds Pharmaceuticals US, Inc.'s assets grew by 1257338.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Apimeds Pharmaceuticals US, Inc. (2021–2025)
The table below shows the annual total assets of Apimeds Pharmaceuticals US, Inc. from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $164.18 Million | +1257338.43% |
| 2024-12-31 | $13.06K | -96.91% |
| 2023-12-31 | $422.08K | +6739.67% |
| 2022-12-31 | $6.17K | -96.42% |
| 2021-12-31 | $172.17K | -- |
About Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.